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Abstract
Transplant infectious disease is a ﬁeld in evolution. For most allograft recipients, immunosuppressive therapies are more potent and have
reduced the incidence of acute allograft rejection. At the same time, these therapies have increased susceptibility to many opportunistic
infections and virally-mediated malignancies. Immunological tolerance has been achieved in only small numbers of patients who avoid drug
toxicities and infection for as long as tolerance persists. The traditional timeline of post-transplant infections remains useful in the
development of a differential diagnosis for patients with infectious syndromes. However, patterns of infection in the post-transplant period
have changed over the past decade. Recipients are derived from a broader range of socioeconomic and geographical backgrounds.
Infections are diagnosed more often, with improved microbiological assays (e.g. nucleic acid testing, NAT) used routinely in the diagnosis
and management of common infections and increasingly in the screening of organ donors. Patterns of opportunistic infection have been
altered by the increased identiﬁcation of organisms demonstrating antimicrobial resistance and by the broader use of strategies to prevent
viral, bacterial and fungal (including Pneumocystis) infections. Newer techniques are being applied (e.g. HLA-linked tetramer binding,
intracellular cytokine staining) to assess pathogen-speciﬁc immunity. These are being integrated into clinical practice to assess individual
susceptibility to speciﬁc infections. Infection, inﬂammation and the human microbiome are recognized as playing a central role in shaping
innate and adaptive immune responses, graft rejection and autoimmunity. The full impact of infection on transplantation is only beginning to
be appreciated.
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Hot Topics
 Consider alterations in the timeline for infection with
institution-speciﬁc strategies for immunosuppression and
prophylaxis.
 Evaluate the cost-effectiveness of newer immunosuppressive
regimens and laboratory assays.
 In resource-limited regions, which forms of immunosup-
pression and prophylaxis are cost-effective?
 The impacts of changes in the human microbiome, vaccina-
tion and antimicrobial therapies on graft survival are poorly
understood. Consider interactions of speciﬁc pathogens
with the innate and adaptive immune systems on graft
function.
General Principles: the Risk of Infection after
Transplantation
The diagnosis of infection is more difﬁcult in transplant
recipients than in immunologically normal hosts due to the
effects of immunosuppression, which obscures the signs and
symptoms of infection both acutely (inﬂammation) and chron-
ically (cellular inﬁltration) [1–3]. Clinical presentations are
ª2014 The Author
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/1469-0691.12593
often complicated by non-infectious causes of fever (e.g. graft
rejection). Drug toxicities and drug interactions (e.g. azole
anti-fungal agents with calcineurin inhibitors) are common.
Multiple simultaneous processes are often present (e.g. graft
rejection and infection). As a result, speciﬁc microbiological
and immunological diagnoses are needed to optimize therapy;
invasive diagnostic procedures are often needed to achieve
timely diagnoses.
One of the general principles of transplant infectious disease
is that the prevention of invasive disease, whether resulting from
new exposure or by the activation of existing, latent infection, is
easier than the treatment of established disease. True toxicity of
prophylaxis with low-dose antivirals, antifungals or daily
trimethoprim-sulphamethoxazole (TMP-SMZ) is uncommon,
although commonly misdiagnosed [1]. Toxicity of the treat-
ment of such infections is common and may be life-threatening
or cause permanent graft injury. In the absence of assays that
allow individualization of immunosuppression after transplan-
tation, prophylactic strategies are based on an assessment of
the anticipated risk of infection based on experience (e.g.
about 15% incidence of Pneumocystis pneumonia in immuno-
suppressed hosts without prophylaxis) or based on the ability
to stratify risk based on serological or microbiological testing,
epidemiological history, and the perceived intensity of immu-
nosuppression. Thus, organ recipients who are colonized with
VRE or Aspergillus or who receive seropositive organs for
cytomegalovirus (CMV) or Epstein-Barr virus (EBV) require
different prophylaxis and/or monitoring at different phases of
the transplant continuum than those who lack such exposures.
The risk of infection is a continuous function of the interplay
between these factors.
Epidemiological exposures
Epidemiological exposures can be divided into four overlapping
categories: donor- and recipient-derived infections, and com-
munity or nosocomial exposures.
Donor-derived infections. Infection is commonly transmitted
with donor organs in the form of latent viral infections of
the graft (e.g. CMV and EBV), infection or unrecognized
colonization of the lungs, unknown bacteraemia or urinary
tract infections, or surgical contamination at procurement or
preservation. Infected organ donors have been found to
transmit bacteria and fungi carrying resistance to routine
surgical antimicrobial prophylaxis [4]. In the past few years,
unexpected clusters of donor-derived infections in transplant
recipients have been recognized, including those due to West
Nile virus, lymphocytic choriomeningitis virus (LCMV), rabies,
HIV, hepatitis B and hepatitis C viruses, herpes simplex virus,
tuberculosis, endemic fungi and Chagas’ disease [4–8]. Con-
troversy persists regarding the use of organs from donors with
undeﬁned clinical syndromes (e.g. ‘altered mental state’ or
fever), which have had a disproportionate role in the
transmission of unusual pathogens associated with central
nervous system infection or bacteraemia. This effect is
ampliﬁed by the shortage of donor organs and the limited
time-frame in which microbiological screening must be
performed. These observations illustrate the need for new
approaches to microbiological screening of donors.
Active or latent infections in transplant recipients should be
eradicated or controlled to the greatest degree possible prior
to transplantation as these will be exacerbated by immuno-
suppression [8]. Common recipient-derived pathogens include
M. tuberculosis, some parasites (Strongyloides stercoralis and
T. cruzi), viral infections (herpes simplex virus (HSV) or
varicella zoster virus (VZV, shingles)), endemic fungi (Histopl-
asma capsulatum, Coccidioidioides immitis and Paracoccidioides
braziliensis), hepatitis B or C or, more recently, HIV. Although
previously contraindicated, successful organ transplantation
has been achieved in HIV-infected patients treated with highly
active antiretroviral therapy (HAART), and in some cases with
HIV-infected organ donors [9,10]. Employment, hobbies,
travel, pets or marijuana use (Aspergillus species) may suggest
clinically important exposures.
Net state of immunosuppression
The concept of the ‘net state of immunosuppression’ com-
prises all factors that may contribute to the risk of infection
(Table 1) [1–3]. The impacts of preexisting disease processes
are often underestimated. Renal failure and dialysis are
associated with poor responses to bacterial infections and
colonization with hospital-acquired ﬂora [11]. Cirrhosis and
portal hypertension reduce acute inﬂammatory responses
(speciﬁc antibody formation, chemotaxis) and predispose to
infection caused by Cryptococcus and Aspergillus species [12,13].
Lung failure may be associated with bacterial and fungal
colonization and poor microbial clearance. These infectious
hazards must be added to the post-transplant effects of
immunosuppressive therapy (Table 2). The effects of some of
TABLE 1. The ‘net state of immune deﬁciency’
Preexisting immune deﬁcits
Critical illness
Malnutrition
Organ dysfunction (uraemia, cirrhosis, COPD/cystic ﬁbrosis, heart failure)
Diabetes
Colonization with antimicrobial-resistant pathogens, hospitalization
Immunosuppressive therapies (current and past)
Acquired immune deﬁciencies (e.g. hypogammaglobulinaemia)
Prior therapies (chemotherapy, antimicrobials)
Mucocutaneous barrier integrity (catheters, lines, drains)
Fluid collections (blood, lymph, urine, bile, pus)
Neutropenia, lymphopenia
Viral co-infection (e.g. CMV, EBV, HCV, HBV, HIV)
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these therapies such as the biological agents (induction therapy
via lymphocyte depletion) are only beginning to be understood
in terms of the repertoire of immune speciﬁcities achieved
during immune reconstitution [14]. Multiple mechanisms of
tolerance (e.g. central vs. peripheral deletion or anergy) have
been demonstrated in patients with induced or spontaneous
immunological graft tolerance. Some gaps in function (e.g. NK
cells, antiviral immunity) persist for months to years. Breeches
in mucocutaneous integrity (e.g. vascular and urinary cathe-
ters) and ﬂuid collections (hematoma, ascites and effusions)
are magnets for microbial seeding.
Prevention of Infection
Antimicrobial prophylaxis has signiﬁcantly altered the inci-
dence and severity of post-transplant infections. Six general
preventive strategies are used: (i) vaccination, (ii) surgical
prophylaxis, (iii) universal prophylaxis, (iv) preemptive or
presymptomatic therapy, (v) ‘targeted prophylaxis’ and (vi)
educated avoidance. ‘Universal prophylaxis’ provides antimi-
crobial therapy to all ‘at-risk’ patients for a deﬁned time
period. ‘Preemptive therapy’ utilizes a sensitive, quantitative
assay (e.g. molecular, antigen detection) to monitor patients
for the presence of a speciﬁc disease at predetermined
intervals to detect early infection prior to the emergence of
invasive disease. Positive assays initiate therapy. Thus, the term
‘presymptomatic’ might be better employed for these inter-
ventions. ‘Targeted prophylaxis’ is a new term for the use of
assays that make possible assessment of the individual’s
susceptibility to speciﬁc pathogens (i.e. prophylaxis in patients
at risk of infection and lacking immunity against that pathogen
based on laboratory assays). Individuals considered to be
over-immunosuppressed based on qualitative assays or inten-
siﬁcation of immunosuppression (e.g. for graft rejection)
should have their primary prophylaxis reinstituted. ‘Educated
avoidance’ includes lifestyle changes that may limit exposure to
potential pathogens (wearing masks or gloves while gardening,
avoiding attics or basements with moulds, and using ﬁltered
water supplies). Preemptive therapy incurs extra costs for
monitoring and coordination of outpatient care while reducing
drug costs and drug toxicities. These are discussed elsewhere
in regard to anti-CMV therapies. Routine surgical prophylaxis
should be adjusted to the organ transplanted and individual
exposures or colonization patterns and hospital epidemiology.
Surgical prophylaxis may be adjusted based on known colo-
nization patterns with organisms such as Pseudomonas, MRSA,
VRE or fungi.
Two advances in prophylaxis have signiﬁcantly altered
transplant medicine. First, trimethoprim-sulphamethoxazole
(TMP-SMZ) is given at most centres for 3 months to a lifetime
to prevent Pneumocystis pneumonia (PCP) as well as Toxo-
plasma gondii, Isospora belli, Cyclospora cayetanensis, many
Nocardia and Listeria species, and common urinary, respiratory
and gastrointestinal pathogens. Low-dose TMP-SMZ is well
tolerated and should be used in the absence of speciﬁc data
demonstrating allergy or interstitial nephritis. Alternative
anti-Pneumocystis prophylactic strategies lack this breadth of
protection [3,15]. The prevention of post-transplant cytomeg-
alovirus and other herpesvirus infections, including the avail-
ability of some oral antiviral agents and the use of
nucleic-acid-based assays to establish a speciﬁc microbiological
diagnosis and to monitor responses to therapy for many viral
infections, have also revolutionized post-transplant care. These
are discussed in detail elsewhere [3].
The Timeline of Infection
The timeline of post-transplant infections reﬂects the
post-transplantation relationship between the recipient’s epi-
demiological exposures and immunosuppressive strategy
employed. The timeline is used to establish a differential
diagnosis for infectious syndromes at various stages after
transplantation. Infections occurring outside the usual period
or of unusual severity suggest excessive immunosuppression
or epidemiologic hazard. The timeline is ‘reset’ to the period of
greatest risk for opportunistic infection with the treatment of graft
rejection or intensiﬁcation of immune suppression (e.g. bolus
corticosteroids or T-cell depletion). Changes in immunosuppres-
sive regimens, routine prophylaxis and improved graft survival
have altered the timeline somewhat. Initial immunosuppression
is evolving from standard ‘triple immunosuppression’ (predni-
TABLE 2. Risk assessment in transplantation
Greater infectious risk
Critical illness entering transplantation
Prior colonization with antimicrobial-resistant pathogens
Induction therapy—lymphocyte depletion
High-dose corticosteroids
Plasmapheresis (not well studied)
High rejection risk (HLA mismatch desensitization)
Early graft rejection
Graft dysfunction
Technical complications
Anastamotic leak
Bleeding
Wound infection/poor wound healing
Prolonged intubation/intensive unit care
Surgical, vascular or urinary catheters
Lower infectious risk
Immunological tolerance
Good HLA match
Technically successful surgery
Good graft function
Appropriate surgical prophylaxis
Effective antiviral prophylaxis
PCP prophylaxis
Appropriate vaccination
ª2014 The Author
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 7), 4–9
6 Clinical Microbiology and Infection, Volume 20 Supplement 7, September 2014 CMI
sone, calcineurin inhibitor and an antimetabolite such as
mycophenylate mofetil; Fig. 1) to a variety of ‘induction’
regimens (T-cell depletion and co-stimulatory blockade) with
calcineurin inhibition and/or mTor inhibition, often with an
antimetabolite [1–3]. The use of induction therapy, notably
with T-cell depletion, requires careful attention to CMV
prophylaxis. Steroid-sparing regimens and anti-Pneumocystis
prophylaxis have made PCP less common. Herpesvirus
infections are uncommon during antiviral prophylaxis. Lym-
phocyte-depleting therapies produce prolonged T- and B-cell
deﬁcits and may alter T-regulatory subsets, antibody produc-
tion and dendritic and NK cell functions. The long-term
impacts of these agents and of the inhibitors of co-stimulatory
T-cell pathways include a prolonged risk of (late, post-pro-
phylaxis) viral and fungal infections and increased risk of
post-transplant lymphoproliferative disorders (PTLD) and
other malignancies. Recent application of antibody depletion
(plasmaphersis), bortezimib and splenectomy in desensitization
protocols diminish opsonization of bacteria and yeasts and
have increased the risk of infection (e.g. encapsulated organ-
isms and yeasts). Sirolimus-based regimens have been associ-
ated with poor wound healing and peripheral oedema, and
with a form of non-infectious pneumonitis easily confused with
PCP or viral pneumonia [16].
Phase 1: early post-transplantation (1–4 weeks)
Opportunistic infections are generally absent in the ﬁrst month
after transplantation as the full impact of immunosuppression
depends on prolonged exposure to suppressive therapies.
Infections in this period are generally donor or recipient
derived (colonization, viraemia and candidaemia) or associated
with technical complications of surgery (e.g. infected haema-
toma and peritonitis). Unexplained early infectious syndromes
(hepatitis, pneumonitis, encephalitis, rashes and leucopenia)
reﬂect donor-derived infection. C. difﬁcile colitis is common.
Early graft injuries (e.g. ischaemia to bile ducts or pulmonary
reperfusion injury) may manifest later as foci for liver or lung
abscesses (Fig. 1).
Phase 2: 1–6 months post-transplantation
In this period, TMP-SMZ prophylaxis should prevent most
urinary tract infections and opportunistic infections such as
FIG. 1. The timeline of post-transplant infections. Redrawn from refs [1–3].
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PCP, L. monocytogenes, T. gondii and sulfa-susceptible Nocardia
species. Some infections (cholangitis, pneumonia and C. difﬁcile
colitis) persist from the perioperative period. Viral pathogens
and graft rejection are responsible for the majority of febrile
episodes in this period. Herpesvirus infections are uncommon
in the face of antiviral prophylaxis but often emerge subse-
quently. Other viral pathogens, including BK polyomavirus,
adenovirus and recurrent hepatitis C virus (HCV), reﬂect the
patient population and intensity of immunosuppression.
Among infections reactivated during this period are the
endemic fungi, Aspergillus species, Cryptococcus neoformans,
Toxoplasma gondii, Trypanosoma cruzi and Strongyloides.
In the past, we have taught that viral infections may cause
immediate or ‘direct’ (tissue invasive) disease or may cause an
array of virus-associated phenomena loosely termed ‘indirect
effects’. These include systemic (CMV) or local (inﬂuenza)
immune suppression predisposing to or enhancing other
opportunistic infections or PTLD and an increased risk of
acute and chronic graft injury or rejection. A signiﬁcant body of
data suggests that ‘indirect effects’ might be better termed
‘microbially-determined immune modulation (MDIM).’
 The microbiome has been redeﬁned in terms of organisms
living synergistically with the host (all forms including
bacteria, viruses, fungi and parasites) and determining some
aspects of host immune function. Acute, latent and chronic
infections participate in these effects. Pertubation or activation
of the microbiome has pleotropic effects in terms of infectious
risk (colonization patterns) and immune function (antigen
speciﬁcity) [17–19].
 Heterologous immunity is immune ‘memory’ of previously
encountered pathogens, which alters subsequent immune
responses to unrelated pathogens or grafts. Thus, prior
antigenic exposures may provoke graft rejection or modu-
late responses to subsequent infections. This may also
suggest that infectious exposures including vaccination will
have both beneﬁcial and detrimental effects in terms of
allogeneic immunity.
 Organisms are also ‘designed’ (often genetic traits co-e-
volved with the human host) to avoid detection or attack by
innate or adaptive immune functions. Thus, CMV has a
genome of 235 Kbp, encoding over 165 genes and over 70
viral proteins. Other than the genes required for viral
replication, many of the known gene products affect the host
cell or immune response to the virus. Immune effects of
parasites (Leshmania sp.) and fungal glycoproteins (glycans)
and their receptors are being described.
 The innate immune system is increasingly recognized as being
essential to the activation and speciﬁcity of adaptive immune
functions. Interactions between microbial antigens and
pattern-recognition receptors on monocyte/macrophages,
dendritic cells and NK cells (e.g. Toll-like receptors and
C-type lectin receptors) are essential to host defences and
to the nature of the response to allogeneic (autoimmunity)
and allogenetic (transplantation) antigens [20–24].
Phase 3: more than 6 months after transplantation
More than 6 months post-transplantation, infectious risk
diminishes as immunosuppression is tapered in recipients with
satisfactory allograft function. These patients tend to develop
more severe manifestations of the common, commu-
nity-acquired infections. Infection may occur in patients
receiving intensiﬁed immunosuppression for graft rejection
without prophylaxis. Chronic viral infections may contribute
to graft injury (e.g. cirrhosis from HCV (livers), bronchiolitis
obliterans (lungs) and accelerated vasculopathy (hearts) with
CMV) or malignancy (PTLD, skin or anogenital cancers). This
group will develop the side-effects of organ dysfunction. One
group tends to have less adequate graft function over time,
often receives more intensive immunosuppression and suffers
recurrent infection despite subsequent attempts at immuno-
suppression minimization. These ‘chronic ne’er-do-wells’ are
at increased risk of opportunistic infection with Listeria or
Nocardia species, invasive fungal pathogens (Zygomycetes and
dematiacious moulds) and unusual organisms (e.g. Rhodococcus
species). Minimal signs of infection merit careful evaluation in
such ‘high-risk’ individuals. They may beneﬁt from lifetime
TMP-SMZ or antifungal prophylaxis.
Future Directions
Given improved immunosuppression, the prevention of infec-
tion has become a cornerstone of modern transplantation.
Individualization of prophylaxis and immunosuppression will
require incorporation of individual factors (genomics, phar-
macogenomics and proteomics) and advanced assays to assess
graft- and pathogen-speciﬁc and non-speciﬁc measures of
cell-mediated ‘immune function’. Multicentre cohorts of
transplant recipients will be required to study the diagnosis
and management of relatively infrequent events such as
virally-mediated malignancies or the role of infection in graft
rejection. Better understanding of the role of the innate
immune system may allow use of a lower intensity of ‘global’
immunosuppression. Tolerance strategies are advancing. Vac-
cines for CMV and other pathogens will alter post-transplant
prophylactic strategies. Improved microbiological diagnostic
tools (e.g. multiplexed assays using a variety of diagnostic
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modalities) will improve donor screening and the diagnosis and
management of invasive infections in transplant recipients.
Investigation of the pathophysiological mechanisms underlying
the pleotropic effects of infection, which predispose the
patient to opportunistic infection and malignancy and graft
rejection, are needed. The role of the microbiome and innate
immunity are beginning to be explored in terms of control of
immune function and speciﬁcities [17–24]. More judicious use
of antimicrobial agents and microbial reconstitution may guide
clinical practice in the future.
Transparency Declaration
The author has no conﬂicts of interest related to the material
presented.
References
1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med
2007; 357: 2601–2614.
2. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the
renal transplant recipient. Am J Med 1981; 70: 405–411.
3. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J
Med 1998; 338: 1741–1751.
4. Doucette KE, Al-Saif M, Kneteman N et al. Donor-derived bacteremia
in liver transplant recipients despite antibiotic prophylaxis. Am J
Transplant 2013; 13: 1080–1083.
5. Fischer SA, Graham MB, Kuehnert MJ et al. Transmission of lympho-
cytic choriomeningitis virus by organ transplantation.[see comment]. N
Engl J Med 2006; 354: 2235–2249.
6. Ison MG, Nalesnik MA. An update on donor-derived disease
transmission in organ transplantation. Am J Transplant 2011; 11:
1123–1130.
7. Srinivasan A, Burton EC, Kuehnert MJ et al. Transmission of rabies
virus from an organ donor to four transplant recipients. N Engl J Med
2005; 352: 1103–1111.
8. Fishman JA, Greenwald MA, Grossi PA. Transmission of infection with
human allografts: essential considerations in the development of donor
screening programs. Clin Infect Dis 2012; 55: 720–727.
9. Roland ME, Stock PG. Review of solid-organ transplantation in
HIV-infected patients. Transplantation 2003; 75: 425–429.
10. Muller E, Kahn D, Mendelson M. Renal transplantation between
HIV-positive donors and recipients. N Engl J Med 2010; 362: 2336–
2337.
11. Clarke IA, Ormrod DJ, Miller TE. Host immune status in uremia. V.
Effect of uremia on resistance to bacterial infection. Kidney Int 1983; 24:
66–73.
12. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis,
intracellular killing and metabolic activity in alcoholic cirrhosis and
hepatitis. Hepatology 1986; 6: 252–262.
13. Fishman JA, Gonzalez RG, Branda JA. Case records of the Massachu-
setts General Hospital. Case 11-2008. A 45-year-old man with changes
in mental status after liver transplantation. N Engl J Med 2008; 358:
604–613.
14. Tchao NK, Turka LA. Lymphodepletion and homeostatic proliferation:
implications for transplantation. Am J Transplant 2012; 12: 1079–1090.
15. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis
spp. in human immunodeﬁciency virus-negative immunocompromised
patients. Clin Microbiol Rev 2004; 17: 770–782.
16. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with
sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343:
225–226.
17. Lathrop SK, Bloom SM, Rao SM et al. Peripheral education of the
immune system by colonic commensal microbiota. Nature 2011; 478:
250–254.
18. Li QR, Wang CY, Tang C, He Q, Li N, Li JS. Reciprocal interaction
between intestinal microbiota and mucosal lymphocyte in cynomolgus
monkeys after alemtuzumab treatment. Am J Transplant 2013; 13: 899–
910.
19. Willner DL, Hugenholtz P, Yerkovich ST et al. Reestablishment of
recipient-associated microbiota in the lung allograft is linked to
reduced risk of bronchiolitis obliterans syndrome. Am J Respir Crit
Care Med 2013; 187: 640–647.
20. Alegre ML, Goldstein DR, Chong AS. Toll-like receptor signaling in
transplantation. Curr Opin Organ Transplant 2008; 13: 358–365.
21. Wang T, Ahmed EB, Chen L et al. Infection with the intracellular
bacterium, Listeria monocytogenes, overrides established tolerance in
a mouse cardiac allograft model. Am J Transplant 2010; 10: 1524–1533.
22. Chen L, Ahmed E, Wang T et al. TLR signals promote IL-6/
IL-17-dependent transplant rejection. J Immunol 2009; 182: 6217–6225.
23. Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition by the
innate immune system. Immunol Rev 2009; 230: 38–50.
24. Kerscher B, Willment JA, Brown GD. The Dectin-2 family of C-type
lectin-like receptors: an update. Int Immunol 2013; 25: 271–277.
ª2014 The Author
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 7), 4–9
CMI Fishman Overview: Infection in Transplantation 9
